Phase 3 mRNA Neoantigen Vaccine Signal: Incremental Gain or Backbone Effect?

Merck and Moderna Lead Cancer Vaccine Race with Melanoma Win

Merck and Moderna have achieved a significant breakthrough in the cancer vaccine field with their mRNA-based personalized neoantigen therapy, intismeran autogene, combined with Merck’s Keytruda. Their Phase 3 data demonstrated extended progression-free survival in patients with cutaneous melanoma, marking a triumphant turnaround for a space that previously faced challenges, exemplified by Dendreon's Provenge. This success validates the approach of individualized, multi-antigen cancer vaccines and sets a new standard for precision patient selection in adjuvant treatment. The partners plan to submit these data to the FDA.

• Merck and Moderna's individualized neoantigen therapy, intismeran autogene, in combination with Keytruda, achieved a "blowout win" in a Phase 3 trial for cutaneous melanoma. The data showed extended progression-free survival compared to Keytruda alone, signifying a major advancement in the treatment of this cancer and validating the efficacy of personalized mRNA-based cancer vaccines.
• The intismeran autogene vaccine works by identifying a patient's unique tumor mutational signature, or "fingerprint," from their own tumor. A personalized mRNA vaccine is then produced to prime the patient's immune system to recognize and attack cells containing this specific antigen fingerprint, offering a therapeutic mechanism to destroy existing tumors and potentially prevent recurrence.
• This success underscores a critical shift in the cancer vaccine landscape, moving away from single-antigen approaches that previously struggled (e.g., Dendreon's Provenge) towards multi-antigen, individualized therapies. Experts highlight the importance of vaccines needing multiple antigens unique to each patient and the emerging standard of biomarker-informed, precision patient selection for adjuvant vaccine development.

Merck and Moderna's Landmark Phase 3 Win in Adjuvant Melanoma

Three recent studies in cutaneous melanoma offer meaningful insights into the efficacy and safety of both targeted and immunotherapeutic strategies.

The COMBI-i trial (parts 1 and 2) evaluated spartalizumab (an anti-PD-1 antibody) in combination with the BRAF inhibitor dabrafenib (150 mg twice daily) and the MEK inhibitor trametinib (2 mg once daily) in 36 patients with previously untreated BRAF V600-mutant unresectable or metastatic melanoma. At a median follow-up of 24.3 months, the triplet regimen achieved an objective response rate (ORR) of 78%, including 44% complete responses. The safety profile was notable: 72% of patients experienced grade ≥3 treatment-related adverse events (TRAEs), all patients required temporary dose modifications, and 17% permanently discontinued all three study drugs due to TRAEs. Biomarker analyses identified low tumor mutational burden, low T cell-inflamed gene expression signature, and high immunosuppressive tumor microenvironment gene expression signature at baseline as factors associated with early progression-free survival events.

The RELATIVITY-047 trial assessed nivolumab plus relatlimab (a LAG-3 inhibitor) against the established comparator nivolumab plus ipilimumab, evaluated via an indirect treatment comparison using inverse probability of treatment weighting. In the overall population of patients with untreated advanced melanoma, nivolumab plus relatlimab demonstrated similar progression-free survival (hazard ratio [HR], 1.08 [95% CI, 0.88 to 1.33]), confirmed objective response rate (odds ratio, 0.91 [95% CI, 0.73 to 1.14]), overall survival (HR, 0.94 [95% CI, 0.75 to 1.19]), and melanoma-specific survival (HR, 0.86 [95% CI, 0.67 to 1.12]) to nivolumab plus ipilimumab. Critically, nivolumab plus relatlimab was associated with a substantially improved safety profile, with grade 3–4 TRAEs occurring in 23% versus 61% of patients, and any-grade TRAEs leading to discontinuation in 17% versus 41%.

A long-term follow-up of a multicenter, single-arm phase IIa trial (NCT02083354) examined dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) in 60 Chinese patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma, 75% of whom had failed prior systemic therapy. At a median follow-up of 37.0 months (95% CI 29.1–44.9), the updated ORR was 71.7% (95% CI 60.3%–83.1%), the median duration of response was 7.5 months (95% CI 4.5 to 10.5), and the 3-year overall survival rate was 28.8% (95% CI 19.1–43.6%) in the overall population and 35.7% (95% CI 15.5–82.4%) in the acral melanoma subgroup. Baseline normal lactate dehydrogenase, fewer than three metastatic organ sites, and complete response to combination therapy were associated with improved progression-free survival and overall survival.

Unpacking Personalized mRNA Cancer Vaccines: Beyond Melanoma

The mechanism of action shared by intismeran autogene (mRNA-4157/V940) — encoding patient-specific tumor neoantigens to drive neoantigen-specific T-cell responses — combined with pembrolizumab has been explored beyond cutaneous melanoma. The phase 1 KEYNOTE-603 study (NCT03313778) provides the clearest evidence of this expansion into other solid tumor indications.

• Non-small cell lung cancer (NSCLC): In Part A of KEYNOTE-603, four patients with resected non-small cell lung cancer received 1-mg mRNA-4157 as adjuvant monotherapy. This represents a single-arm, monotherapy intervention model in a resected solid tumor setting, distinct from the combination approach used in melanoma.

• Resected cutaneous melanoma with combination therapy: Part D of KEYNOTE-603 enrolled 12 patients with resected cutaneous melanoma receiving 1-mg mRNA-4157 plus 200-mg pembrolizumab, serving as the combination intervention arm within the same phase 1 study. This arm provided mechanistic proof of concept — demonstrating sustained neoantigen-specific T-cell responses and expansion of cytotoxic CD8 and CD4 T cells — that supported further development across resected solid tumors broadly.

• Pancreatic cancer and glioblastoma: RNA-based cancer vaccine platforms, including mRNA-4157 combined with pembrolizumab, are noted in the broader RNA vaccine landscape as part of a pivotal 2024–2025 development period that includes "breakthrough results from pancreatic cancer vaccines and novel glioblastoma treatments using layered nanoparticle delivery systems." The knowledge base does not have sufficient information on this aspect regarding the specific intervention models for these indications.

• Broader solid tumor rationale: The KEYNOTE-603 findings were described as providing "mechanistic proof of concept to support further development of mRNA-4157 for patients with resected solid tumors," indicating the intervention model — adjuvant administration following complete resection, either as monotherapy or in combination with pembrolizumab — is the framework being extended across tumor types beyond melanoma.

The Evolving Cancer Vaccine Landscape Post-Melanoma Breakthrough

The treatment landscape for cutaneous melanoma has undergone substantial evolution, driven by advances in both targeted therapy and immune checkpoint inhibition. In the BRAF-mutant population, three approved BRAF inhibitor/MEK inhibitor combination regimens — dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib — have been evaluated in randomized phase III trials (COMBI-v, coBRIM, and COLUMBUS, respectively). Although no head-to-head comparisons exist, a side-by-side analysis of these trials demonstrated that median progression-free survival and overall response rate were similar across regimens, with numerically higher values observed with encorafenib/binimetinib. Median overall survival was numerically longer with encorafenib/binimetinib (33.6 months) compared to dabrafenib/trametinib (25.6 months) and vemurafenib/cobimetinib (22.3 months). Each combination displayed a distinct safety profile, with higher incidences of pyrexia associated with dabrafenib/trametinib and photosensitivity reactions with vemurafenib/cobimetinib. In the COLUMBUS trial, encorafenib plus binimetinib also demonstrated a positive impact on health-related quality of life, with patients showing improvement in FACT-M and EORTC QLQ-C30 global health status scores compared to vemurafenib.

In the immune checkpoint inhibitor space, the fixed-dose combination of nivolumab and relatlimab-rmbw — a programmed death-1 inhibitor and lymphocyte-activating gene 3 inhibitor, respectively — received regulatory approval for unresectable or metastatic melanoma following results from the RELATIVITY-047 trial. That trial demonstrated a median progression-free survival of 10.1 months with the combination versus 4.6 months with nivolumab monotherapy (hazard ratio 0.75; 95% CI, 0.62–0.92; P = 0.006), with grade 3 or 4 adverse events occurring in 18.9% of patients on combination therapy compared with 9.7% on nivolumab alone. However, the subsequent phase 3 RELATIVITY-098 trial, evaluating nivolumab plus relatlimab as adjuvant therapy following complete resection of stage III/IV melanoma, did not demonstrate a recurrence-free survival benefit over nivolumab alone (hazard ratio = 1.01; 95% CI: 0.83–1.22; P = 0.928). Translational analyses from that trial suggested lower circulating LAG-3 T cells in the adjuvant setting compared to the advanced disease setting, which may explain the absence of added benefit in resected melanoma.

The adjuvant and neoadjuvant settings have also seen meaningful shifts. Phase III adjuvant trials have demonstrated significant recurrence-free survival improvements with pembrolizumab and the dabrafenib-trametinib combination (for BRAF-mutant melanoma) versus placebo, and both nivolumab and pembrolizumab have shown significant recurrence-free survival improvements compared with ipilimumab 10 mg/kg. A network meta-analysis further indicated that the risk of recurrence with nivolumab was similar to pembrolizumab and lower than ipilimumab 3 mg/kg, ipilimumab 10 mg/kg, or interferon; while the risk of recurrence with nivolumab was similar to dabrafenib plus trametinib at 12 months, it was lower beyond 12 months (hazard ratio at 24 months: 0.46 [95% credible interval: 0.27–0.78]; at 36 months: 0.28 [0.14–0.59]). In the neoadjuvant setting, the SWOG S1801 cooperative group trial reported superior event-free survival with neoadjuvant versus adjuvant therapy, and real-world data from the University Hospital Zurich corroborated the feasibility of neoadjuvant immunotherapy protocols, with 9-month event-free survival of 77% in the NADINA cohort and 74% in the SWOG S1801 cohort, though major pathologic response rates in the real-world NADINA cohort were lower than those observed in the phase III trial.

Personalized mRNA Vaccines: Reshaping Adjuvant Melanoma Treatment

The recent announcement regarding the mRNA-based personalized neoantigen therapy, mRNA-4157 (V940), combined with pembrolizumab, represents a significant stride forward in oncology. For patients with resected high-risk cutaneous melanoma, the Phase 2b KEYNOTE-942 study demonstrated a notable improvement in recurrence-free survival when the personalized vaccine was added to pembrolizumab monotherapy. This finding is particularly impactful given that pembrolizumab alone is already a well-established adjuvant therapy for melanoma, having shown sustained benefits in long-term analyses.

This success validates the core concept of individualized neoantigen vaccines, which are designed to stimulate specific T-cell responses against a patient's unique tumor mutations. Studies have consistently shown these vaccines can induce de novo and expand existing neoantigen-specific T cells, a crucial mechanism for anti-tumor activity. The implications extend beyond melanoma, as similar mRNA-based personalized vaccines are demonstrating immunogenicity and early clinical activity in other challenging cancers like pancreatic ductal adenocarcinoma and hepatocellular carcinoma, suggesting a broad applicability for this platform.

However, the path forward is not without its considerations. While the clinical benefit is compelling, the p-value for the primary endpoint in the Phase 2b study was borderline, underscoring the need for confirmatory Phase 3 data. Furthermore, the personalized nature of these vaccines, requiring real-time synthesis from individual tumor biopsies, presents complex manufacturing and logistical hurdles for widespread commercialization. Finally, while T-cell responses are robust, the efficacy of therapeutic vaccination can still be constrained by the immunosuppressive tumor microenvironment, particularly in later disease stages. Optimizing patient selection and combination strategies will be key to maximizing the clinical potential of these innovative therapies.